Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.61 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 7/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30758642 | 0.91 | MAPT (0.54) | TERTADAMTS5SRCMAPTKMT2A | |
| SCHEMBL5508642 | 0.91 | MAPT (0.54) | TERTADAMTS5SRCMAPTKMT2A | |
| SCHEMBL12516864 | 0.89 | TERT (0.51) | TERTADAMTS5SRCMAPTKMT2A | |
| SCHEMBL30631693 | 0.87 | SRC (0.60) | SRCMAPTKMT2ANPC1RAB9A | |
| SCHEMBL6849018 | 0.87 | SRC (0.60) | SRCMAPTKMT2ANPC1RAB9A | |
| SCHEMBL415226 | 0.86 | HPGD (0.55) | TERTADAMTS5SRCMAPTKMT2A | |
| SCHEMBL30715071 | 0.86 | HPGD (0.55) | TERTADAMTS5SRCMAPTKMT2A | |
| SCHEMBL11217503 | 0.86 | HPGD (0.55) | TERTADAMTS5SRCMAPTKMT2A | |
| SCHEMBL6852137 | 0.85 | SRC (0.58) | SRCMAPTKMT2ANPC1RAB9A | |
| SCHEMBL6856729 | 0.83 | SRC (0.56) | SRCMAPTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-2794620-B1 | BODIPY STRUCTURE FLUORESCENCE PROBES FOR DIVERSE BIOLOGICAL APPLICATIONS | NAT UNIV SINGAPORE (SG) | 2017-11-15 | — | — | EP | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9169224-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-27 | — | — | US | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0818431-A1 | Scavenger assisted combinatorial process for preparing libaries of secondary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0816310-A2 | Scavenger assisted combinatorial process for preparing libraries of tertiary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0636124-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021170-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1993-10-28 | — | — | WO | disclosed |
| US-4592876-A | Arylglyoxals | AMERICAN CYANAMID COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| US-4474810-A | HYPOGLYCEMIC AGENTS, ANTIDIABETIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0114389-A2 | Substituted arylglyoxal derivatives | AMERICAN CYANAMID COMPANY (US) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | TERT 3032/4885ADAMTS5 2684/4885SRC 1979/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | TERT 3032/4885ADAMTS5 2684/4885SRC 1979/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | TERT 2813/4885ADAMTS5 2422/4885SRC 2015/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | TERT 2813/4885ADAMTS5 2422/4885SRC 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.